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2Abstract
Dual-drug-loaded pH-responsive fiber scaffolds were successfully prepared by coaxial
electrospinning. These were designed with the aim of being sutured into the resection site after
tumor removal, to aid recovery and prevent cancer recurrence. The shell was made up of a
mixture of gelatin and sodium bicarbonate (SB, added to provide pH-sensitivity), and was
loaded with the anti-inflammatory drug ciprofloxacin; the core comprised
poly(lactide-co-ε-caprolactone) with the chemotherapeutic doxorubicin hydrochloride (DOX). 
Scanning electron microscopy revealed most fibers were smooth and homogeneous, with
average diameters of 750-850 nm. Transmission electron microscopy demonstrated the
presence of a clear core/shell structure in all the materials. The fiber scaffolds were further
characterized using infrared spectroscopy and X-ray diffraction, which proved that both drugs
had been successfully loaded into the fibers in the amorphous form. The gelatin shells were
cross-linked with glutaraldehyde to enhance their stability, and water contact angle
measurements used to confirm they remained hydrophilic after this process, with angles
between 10 and 35º. This is important for onward applications, since a hydrophilic surface is
known to encourage cell proliferation. During in vitro drug release studies, a rapid and
acid-responsive release of ciprofloxacin was seen, accompanied by sustained and long-term
DOX release. Both the release profiles and the mechanical strength of the fibers can effectively
be tuned through the SB content of the fibers: for instance, the break stress varies from 2.00
MPa to 2.57 MPa with an increase in SB content. The pH values of aqueous media exposed to
the scaffolds decrease only slightly, by less than 0.5 pH units, over the two-month timescale,
suggesting that only minimal fiber degradation occurs during this time (HCl from the DOX salt
and the degradation products of gelatin and PLCL are all acidic materials, and will cause a
reduction in pH of the immersion medium if freed into solution). The fiber scaffolds also have
good biocompatibility, as revealed by in vitro cytotoxicity experiments. Overall, our results
demonstrate that the novel scaffolds reported here are promising pH-sensitive drug delivery
systems, and may be candidates for use after tumor resection surgery.
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3Introduction
In this work, we sought to develop pH-responsive dual-drug loaded systems to be applied
to tumor resection sites with the aim of preventing both infection and the recurrence of cancer.
To do this, we employed the electrospinning technology, a simple route to prepare nanoscale
fibers that has been widely explored in the context of biomaterials 1. The simplest experiment,
single-fluid spinning, applies electrical energy to a polymer solution containing a functional
component (e.g. a drug), to yield monolithic fibers. A more sophisticated variant is coaxial
electrospinning, where two different solutions are flowed through two concentrically arranged
needles to produce core/shell architectures. Electrospinning’s simplicity, low cost, and the fact
that a wide variety of materials can be processed, have led to many reports of electrospun
fibers 2, 3.
Coaxial fibers have several benefits over the monolithic fibers from single fluid spinning,
as a result of their more complex architectures allowing greater control over functional
performance. For instance, a core/shell structure can extend the period over which drug
contained in the core is released if the shell comprises a blank polymer layer. In one such study,
Yu et al. 4 used poly(ε-caprolactone) (PCL) as the shell polymer and a mixture of a protein and 
polyethylene glycol as the core, and explored the relationship between drug release rate and
shell thickness. It was found that a thicker shell layer slows down the rate of release. Drexler
and co-workers 5 prepared fibers with a PCL shell and gelatin core, and determined that the
two polymers together led to materials with high biocompatibility (as a result of gelatin) and
good mechanical properties (from PCL). In other work, Duan et al. selected PCL as the core
polymer and collagen as the shell, producing fibers which possess both good mechanical
strength and high biocompatibility, and which they proposed might be used in vascular tissue
engineering 6.
The tumor microenvironment is rather more acidic than the physiological pH, and higher
temperature 7, 8, which offer the opportunity to target therapies. A number of pH-sensitive drug
delivery systems have been reported. For example, Ulbrich et al. 9 synthesised hydrolyzed
poly(maleic anhydride) and N-(2-hydroxypropyl) conjugates of acrylamide, and linked
doxorubicin (DOX) to the polymer backbone. These conjugates were found to be stable at pH
47.4 but released their drug cargo at pH 5. Further, Chiang and co-workers 10 prepared a dual
pH- and temperature-sensitive DOX-loaded nanogel based on pol(N-isopropylacrylamide);
they were able to use temperature changes to regulate the loading of DOX, and control its
release by changing the pH.
A number of electrospun systems with pH sensitivity have been reported. These typically
used a pH-sensitive polymer (such as a Eudragit) as the basis for the fibers. Another route to
achieve this is to use sodium bicarbonate (SB). For instance, Zhao et al. 11 fabricated
acid-responsive electrospun fibers using an emulsion method (loading SB and ketoprofen into
PLLA fibers), and in a previous study we found that preparing gelatin fibers loaded with SB
can lead to the pH-responsive release of ciprofloxacin 12. In other work, Ke and co-workers 13
prepared a drug delivery system based on microspheres of poly(lactic-co-glycolic) acid
containing DOX and SB, which exhibited the ability to target intracellular compartments with
pHs lower than the general physiological pH. The incorporation of SB leads to acid sensitivity
because it reacts with protons at low pH, generating CO2 gas. This produces pores or ruptures
in the drug-carrying vehicles, rapidly releasing the incorporated active ingredient. Thus, SB
has been demonstrated in these pioneering studies to offer a simple and low-cost route to acid
sensitivity. However, all these studies only looked at a single active ingredient.
The development of new cancer medicines is of great importance: data from the World
Health Organization show that by 2020 the global incidence of cancer will increase by 50%
over 2003 levels, which equates to an additional 15 million cancer patients per year 14. The
main treatments for cancer have comprised surgery, radiotherapy, and chemotherapy. In
general, surgical resection is the most effective treatment where tumors are accessible 15.
However, this can induce an infection, and inflammation associated with tumor-infiltrating
inflammatory cells can affect the efficacy of adjuvant chemotherapies used alongside surgery.
Chemotherapy also generally uses high doses of the relevant active ingredients, which leads ot
numerous toxic side effects on the body. Regardless of the treatment used, recurrence of cancer
is very common: relapse is seen in one of every five cancer cases 16.
One area of drug delivery in which electrospun fibers have attracted particular attention is
that of anti-cancer medicines. In one example, Sedghi and co-workers 17 recently developed a
curcumin-loaded monolithic system based on poly(vinyl alcohol) and chitosan, which they
5proposed have to applications in post-operative chemotherapy. In another, doxorubicin
(DOX)-loaded mesoporous silica nanoparticles were incorporated into poly(L-lactic acid)
(PLLA) fibers via electrospinning, giving systems from which DOX was released in a
sustained manner 18.
In this paper, we sought to build on the literature reports to make multi-functional
materials with both anti-inflammatory and anti-cancer properties. To do this, we fabricated
acid-responsive fiber scaffolds carrying ciprofloxacin and DOX. The intention is that the fiber
scaffolds can be sutured into the resection site after tumor removal. They were thus designed to
provide an initial short-term release of ciprofloxacin, to inhibit any infection and
post-operative inflammation, followed by long-term DOX release to destroy any residual
cancerous tissue and avoid recurrence. The experimental rationale is illustrated in Figure 1. A
series of systems with different SB contents were prepared in the hope of tuning the drug
release and mechanical properties. For the latter, we envisage that the scaffolds would be
sutured into the resection site post-surgery to secure them in place 19-21. This requires them to
have a break stress in the range of 2 to 5 MPa 22, 23.
Ciprofloxacin is a quinolone drug which offers broad-spectrum antimicrobial activity
with no serious side effects 24. It was selected for inclusion in the fiber shell, with the goal of
preventing post-operative infections. Doxorubicin hydrochloride, included in the core, is an
anti-tumor drug which inhibits the synthesis of nucleic acids and has broad anti-tumor activity.
The core polymer is poly(lactide-co-ε-caprolactone) (PLCL), which can be fully hydrolyzed 
in vivo. The final degradation products of PLCL are water and carbon dioxide, and the
intermediate products (lactic acids) are harmless to the human body in small quantities 25.
PLCL thus has good biocompatibility and does not lead to any toxic side effects in vivo. It has
been widely used in tissue engineering of cartilage, bone, blood vessels, the liver, and the
heart, inter alia 26, 27. The presence of PLCL in the fibers made in this work can impart the
fiber scaffolds with suitable mechanical properties to act as a tissue engineering scaffold in
the later stages of post-operative recovery, and since it hydrolyzes slowly 28, 29 should give
sustained release of the embedded DOX to prevent recurrence. The shell polymer, gelatin, is a
naturally occurring material with good biocompatibility and biodegradability, as well as a
6high degree of hydrophilicity 30. It will thus ensure the fiber scaffolds produced have a
hygroscopic exterior, which is expected to enhance biocompatibility.
Experimental section
Materials
Gelatin (powder, purity > 99.5%) and glacial acetic acid were obtained from the
Sinopharm Chemical Reagent Co., Ltd. Doxorubicin hydrochloride (DOX, purity > 99%) was
procured from J&K Scientific Co. Ltd, while dimethyl sulfoxide (DMSO), and
poly(lactide-co-ε-caprolactone) (PLCL) (PCL:PLLA=1:1, Mw=34.5×104 g mol-1) were
purchased from Jinan Daigang Biomaterials Co., Ltd. RPMI 1640, DMEM and fetal bovine
serum (FBS) were sourced from Jinuo Biological Medicine Technology Ltd.
1,1,1,3,3,3-Hexafluoroisopropanol (HFIP, purity > 95.5%), ciprofloxacin (purity>98%),
phosphate-buffered saline (PBS, pH=7.4), sodium bicarbonate (SB), penicillin/streptomycin,
and Thiazolyl Blue Tetrazolium Bromide (MTT) were purchased from Sigma-Aldrich Ltd. An
acetate buffer (AA, pH=5.0) was prepared in-house. SMMC-7721 and L929 cells were
provided by the Institute of Biochemistry and Cell Biology (Chinese Academy of Sciences).
Electrospinning
A stainless steel co-axial spinneret (Changsha Nayi) was used for electrospinning. The
spinneret dimensions were as follows: core needle inner diameter (ID) 0.346 mm and outer
diameter (OD) 0.607 mm; shell needle ID 1.138 mm and OD 1.476 mm. A simple flat-tipped
needle with an internal diameter of 0.5 mm was also employed to prepare monolithic control
fibers. The core and shell solutions were prepared in HFIP, as detailed in Table 1 (“G”
denotes gelatin, “P” PLCL, and “S” sodium bicarbonate; “+” indicates systems with a drug
loading, and “-” those without drug). All solutions were stirred for 24 hours on a magnetic
stirrer to ensure complete dissolution.
For electrospinning, the appropriate solutions were loaded into 5 mL plastic syringes,
and expelled through the co-axial spinneret with shell and core flow rates of 0.7 mL h-1 and
0.3 mL h-1 respectively. A high voltage power supply (ZGF-2000, Shanghai Sute Electrical
7Co. Ltd.) was used to apply a voltage of 17 kV between the spinneret and an aluminium
collector plate (10 × 10 cm). Two syringe pumps (KDS100, Cole-Parmer) were used to drive
the working fluids. The distance between the spinneret and collector plate was 23 cm. Control
monolithic gelatin and PLCL fibers were similarly prepared, using a single needle and a flow
rate of 0.5 mL h-1.
All experiments were performed at 25 ºC and 33-45 % relative humidity. After about 7
hours of electrospinning, the resultant fiber mats were dried in a vacuum chamber (DZF-6050,
Shanghai Laboratory Instrument Work Co. Ltd.) for 48 hours at 25 ºC. The gelatin shells were
then crosslinked. To do this, an aqueous solution of glutaraldehyde (25.0-28.0 % (v/v); 10 mL)
was placed in a Petri dish at the bottom of a brown translucent desiccator, with the fibers
above them. Crosslinking was allowed to proceed in the glutaraldehyde vapor for 9 h. All of
the polymer solutions and fiber scaffolds containing DOX were stored away from light in
order to prevent any degradation.
Fiber morphology
Fiber samples (1 × 1 cm) were mounted on metal stubs using conductive double-sided
tape, and then sputter coated with platinum under argon for about 40 s. A scanning electron
microscope (SEM; JSM-5600 instrument, JEOL) was employed to investigate the
morphological characteristics of the fibers. The ImageJ software (National Institutes of
Health) was used to analyze the average diameter of each fiber sample. Around 50 fibers in
the SEM images were randomly selected for this purpose.
Transmission electron microscopy (TEM; H-800 instrument, Hitachi) was additionally
used to confirm the core/shell structure of the fibers. Samples for TEM were prepared by
spinning directly onto copper TEM grids for a few seconds.
Fiber characterization
The water contact angles of the fiber surfaces were determined using a 322W instrument
(Thermo Cahn). A water droplet (ca. 1 µL) was placed onto the surface of the fibers for this,
with at least 10 measurements made (at 25 ºC) per fiber sample. Fourier-transform infrared
spectroscopy (FTIR) was performed on a Nicolet-Nexus 670 FTIR spectrometer (Nicolet
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cm-1. X-ray diffraction (XRD) patterns were collected over the 2θ range 6-70° on a 
D/Max-BR diffractometer (Rigaku) supplied with Cu Kα radiation (40 kV/30 mA, λ = 1.5418 
Å). The mechanical properties of the cross-linked fibers were quantified on a HY-9940FS
tensile testing machine (Shanghai Heng Yuyi Co., Ltd). Measurements were performed at 25
ºC and a relative humidity of 70 %; samples of the fiber scaffolds of 1 × 5 cm (thickness 0.1 -
0.2 cm) were cut for these experiments. Five measurements were made for each fiber sample,
and the results are reported as mean ± S.D.
In vitro ciprofloxacin and DOX release
The cross-linked drug-loaded fibers (100 mg) were immersed in centrifuge tubes
containing 20 mL of PBS (pH=7.4) or acetate buffer (pH=5.0). The samples were incubated
in a constant temperature incubator shaker at 37 ºC for three weeks, with mild shaking (100
rpm). At predetermined time points, 1 mL of the test medium was withdrawn and an equal
amount of fresh preheated PBS or AA buffer solution was added. The amount of drug
released was quantified using a UV spectrophotometer (UV-1800, SHJH Company) at 277
nm (ciprofloxacin) or 480 nm (DOX), following construction of a calibration curve. Dilution
was corrected for in the release calculations, and the cumulative release is expressed as a
percentage of the theoretical drug loading in the fibers. Three measurements were made for
each fiber sample, and the results are reported as mean ± S.D.
Antibacterial activity
The antibacterial activity of the fibers was measured using the zone of inhibition test
method in Luria–Bertani medium. E. coli (ATCC 29522) and S. aureus (ATCC 6538) were
used as model gram-negative and gram-positive bacteria. The crosslinked fiber scaffolds were
cut into circular discs (diameter ca. 14 mm), then disinfected with three 2 h cycles of
exposure to UV radiation prior to use. Bacteria were cultivated in the liquid medium for 12 h
at 37 ºC in a rotary shaker. The pH of the medium was then adjusted to 6.8, and 100 μL (105
colony forming units) of the bacteria loaded into a petri dish by the plate coating method.
Next, the fiber samples were placed onto the plates. All the dishes were cultured at 37 ºC for
912 h, before zones of inhibition were measured. Five measurements were made for each fiber
sample, and the results given as mean ± S.D.
In vitro cytotoxicity experiments
SMMC-7721 (a human liver cancer cell line) was employed to study the efficacy of the
fibers in inducing the death of cancer cells, and L929 (mouse fibroblast) cells as a model
non-cancerous cell line to explore the cytotoxicity of the scaffolds to normal cells. These cells
were cultured in RPMI 1640 and DMEM medium, respectively. Before use, both RPMI 1640
and DMEM medium were supplemented with 1% (v/v) of a pre-made penicillin (100 units
mL-1) and streptomycin (100 units mL-1) solution, and 10% (v/v) fetal bovine serum. Cells
were cultured in an incubator at 37 ºC and 5 % CO2. Prior to experiments, trypsinization was
used to separate the cells from the culture flask, after which they were recovered by
centrifugation and diluted to a density of 2.0 × 104 cells mL-1. Fiber samples for in vitro
studies were directly electrospun onto 14 mm cover slips, with 20 cover slips placed on the
collector and electrospinning conducted for 7 h. The fibers were cross-linked with
glutaraldehyde, and any residual glutaradehyde vapour allowed to evaporate before cell
culture experiments were performed.
The fiber-coated cover slips were placed in the wells of 24-well plates, with fiber-free
slips as a negative control. The 24-well plates were sterilized under alcohol steam for 48 h
and then washed twice with PBS to remove any residual ethanol. Next, 400 μL of RPMI 1640 
(for SMMC-7721 cells) or DMEM (for L929 cells) was added to each well and the plate
incubated for 0.5 h before 200 μL of dissociated SMMC-7721 or L929 cells at a density of 2.0 
× 104 cells mL-1 were seeded directly into each well. After 1, 3, or 5 days, the medium in each
well was replaced by 40 μL of MTT solution (0.5 % w/v) and 360 μL of fresh RPMI or 
DMEM. After incubation for 5 h, 400 µL DMSO was added to each well, and the plate placed
on a shaker for 30 min at room temperature. Cell viability was then quantified in terms of
absorption at 570 nm with the aid of a microplate reader (Multiskan, Thermo-Fisher). Each
experiment contained triplicate conditions, with three independent experiments performed.
Degradation studies
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Approximately 0.1 g of each fiber sample was soaked in 20 mL of PBS or AA buffer
solution in a 37 ºC incubator. After either 3 days or 2 months of incubation, the fiber samples
were recovered, and surface water removed. 1 × 1 cm samples were cut from the mats and
analysed using SEM. The pH of the immersion medium was also quantified using a pH meter
(PHS-3C, Inesa Instrument Co. Ltd). Five measurements were made for each fiber sample.
Statistical analysis
The experimental data are presented as mean ± SD. Statistical analysis was undertaken
using one-way ANOVA. The threshold significance level was set at 0.05. Thus, p (probability)
values lower than 0.05 were considered statistically significant.
Results and discussion
Fiber morphology
Figure 2(a)-(d) depict SEM images of G+ / P+, GS1+ / P+, GS2+ / P+, and GS3+ / P+, and
reveal that the fiber scaffolds are largely smooth and homogeneous. The SEM images for
GS1- / P-, GS1- / P-, GS2- / P-, and GS3- / P- can be found in the Supplementary Information,
Figure S1. Clearly, most of the fiber diameters are homogeneous, but some very fine fibers
can also be observed. The diameter of the fibers increase with drug loading, which is
presumably a result of the greater amount of solute per unit volume dispensed. The addition
of SB causes the fiber diameters to become slightly larger (compare for instance Figure 2(a)
and (b)), but the amount of SB added has little effect on diameter. The diameters of
monolithic drug-loaded gelatin and PLCL fibers have previously been reported to be smaller
than these coaxial materials, at 603 ± 126 nm and 732 ± 130 nm respectively 12.
Figure 2(e)-(h) show the drug-loaded fibers after cross-linking. The morphology has
barely changed, but the fibers have become larger. There is also a decrease in the void
volume of the fiber scaffolds after crosslinking, and they become slightly yellow in colour.
Crosslinking with glutaraldehyde involves the reaction of free amino groups on the gelatin
polypeptide chains with the aldehyde groups of glutaraldehyde (forming aldimine [CH=N]
linkages) 31. In the first step, the nucleophilic addition of ε-NH2 groups to carbonyl groups of
the aldehyde results in the formation of carbinolamine, which is unstable. In the second step,
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protonation of the -OH group followed by loss of an H2O molecule leads to conjugated Schiff
bases being generated. Therefore, new covalent bonds are formed between gelatin molecules
both intramolecularly and intermolecularly. These result in the fiber scaffolds' mechanical
strength and water resistance improving significantly, with an increased tensile strength
having been reported after crosslinking 32. The SB content (or lack thereof) has no effect on
the post-cross-linking diameters.
TEM images (Figure 3 and S1) show the drug-loaded fibers to have a clear core/shell
structure. As the SB concentration increases, some solid particles (assumed to be SB) can be
seen in the shell. This is expected to be because the concentration was above its saturation
solubility, and thus the shell working fluid comprised a suspension at higher concentrations.
Nevertheless, at an SB concentration of 5 % w/v clear compartmentalized fibers can still be
seen. However, when the SB content reaches 7%, a phase separation phenomenon arises. The
GS4+ / P+ system shows a large number of solid particles on the surface of fibers by SEM, and
no clear coaxial structure in TEM (see Figure S2). This formulation was thus excluded from
further analysis.
Further characterization
FTIR spectra can be found in Figure 4. Gelatin has peaks at 3296 cm-1 attributed to -OH
or -NH stretching, and two broad peaks at about 1659 cm-1 and 1539 cm-1, which correspond
to the stretching of the C=O group (amide I), and the combined bending of N-H and
stretching of C-N in the amide II band 33, 34. The characteristic band of PLCL at 1758 cm-1
arises from ester bonds (-C(=O) O-), while that at 2943 cm-1 corresponds to methylene (-CH2)
groups. Ciprofloxacin has peaks at 3050 cm-1 (attributable to O-H stretching), 1620 cm-1
(C=O stretching), 1600 cm-1 and 1500 cm-1 (benzene ring stretching vibrations). Absorbance
bands are observed for DOX at around at 3310 cm-1 and 2933 cm-1 as a result of -NH2 and
-CH stretching, while those at 1350 cm-1 and 1070 cm-1 arise from C-H stretching and the
asymmetric stretching vibration of the ether linkage (C-O-C).
The drug-loaded fibers contain characteristic bands at 2943 cm-1, 1659 cm-1 and 3296
cm-1 which are correlated with the presence of both PLCL and gelatin. The presence of the
drugs is less clear, because their distinctive vibrations (e.g. that of DOX at 3050 cm-1) overlap
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with those of gelatin and PLCL. This can most likely be ascribed to the low drug loading and
these peaks being masked by gelatin.
X-ray diffraction patterns of the fibers (Figure S3) show only broad haloes, demonstrating
a lack of long-range order. The fibers hence comprise amorphous systems, with the drugs
distributed in them at the molecular level 35.
Contact-angle data and mechanical properties
Contact-angle data were collected to assess the wettability and hydrophilicity of the fiber
membrane surfaces. This is important because it impacts the biocompatibility of the scaffolds,
and the ability of cells to adhere to and proliferate on them. The results for all the samples are
summarized in Table 2. As expected, the fibers with gelatin shells all have hydrophilic
surfaces, with contact angles below 35º. PLCL is hydrophobic, and accordingly PLCL fibers
have a high contact angle of > 120º. The contact angle of the fibers decreases with an increase
in the SB content in the shell, but only for SB concentrations up to 3% w/v (GS2+ / P+): a
further increase in the concentration to 5% w/v in GS3+ / P+ makes little difference. Generally
speaking therefore, increasing the concentration of SB appears to increase the hydrophilicity
of the fibers. Comparing the drug-free and drug-loaded fibers, it can be seen that the addition
of ciprofloxacin and DOX reduces the contact angle slightly, owing to their hydrophilic
nature.
Appropriate mechanical properties are necessary for scaffold materials. To probe the
mechanical properties of the electrospun scaffolds, their tensile strength was measured for the
monolithic gelatin and PLCL fibers, and the coaxial fiber scaffolds. Representative results are
shown in Figure 5.
All the fibers display similar behavior, as can be seen from the full data set in Table 3.
The two components of the fiber act synergistically to optimize the mechanical properties:
PLCL has high strength, and as a result the coaxial fibers show higher tensile strength values
then gelatin alone. Conversely, gelatin has higher elongation at break, which is also imparted
on the coaxial fibers such that they stretch more than pure PLCL before breaking. The
addition of gelatin in the core/shell fibers reduces this dramatically, to < 0.1 MPa, very close
to the value for pure gelatin fibers. The results obtained are in line with those found in the
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literature. For instance Jaiswal et al. 36, prepared two types of
polycaprolactone-gelatin-hydroxyapatite scaffolds. One scaffold was prepared by depositing
hydroxyapatite on electrospun polycaprolactone-gelatin fibers, and the second by blend
electrospinning. The break stress of the scaffolds was found to be ca. 3 MPa and ca. 1 MPa
respectively. The agglomeration of hydroxyapatite particles reduced the mechanical
properties of the blend electrospun scaffold. In another study by Yaszemski 37, a synthetic
material to replace trabecular bone was developed and found to have a break stress of ca. 5
MPa. Zhou 38 prepared a regenerated silk fibroin tubular scaffold using electrospinning, and
found it to have a tensile strength of 3.57 MPa, suitable for use in small-diameter vascular
grafts. Our fiber scaffolds are found to have break stresses within the range 2-2.6 MPa and
elongation at break of > 20%. This suggests that they match the requirements for being
sutured (a break stress of 2-5 MPa 23), and thus are suitable for use as implants in resection
sites.
Drug release
Figure 6 presents ciprofloxacin release profiles from the fiber scaffolds (prepared as in
Table 1) in PBS (pH=7.4) or AA (pH=5.0). While the sodium bicarbonate (SB)-free systems
behave very similarly in both PBS and AA, acidic conditions are found to promote
ciprofloxacin release in the SB-containing fibers. The latter bodes well for their use in treating
infection, given that inflammation is known to lower the local pH 39. The pH-sensitivity arises
because at low pH CO2 gas is generated as SB reacts with protons 40, creating channels and
forming a porous structure through which the drug molecules can diffuse into the release
medium (see Figure 1). Typically, infections arise in the first few days after surgery 41, 42, and
thus the release rates observed from the fiber scaffolds match well with the clinical
requirement.
DOX release data can be found in Figure 7. Release from a uniaxial PLCL fiber scaffold
(Figure 7(a)) shows rapid release over ca. 20 hours in PBS (pH=7.4). In contrast, DOX
release from the coaxial fibers in either PBS or AA buffer is much extended (Figure 7(b)) as a
result of the core/shell structure 43. As with ciprofloxacin, pH-sensitivity is observed for the
SB-containing fibers, with more rapid release in AA. This is promising for the treatment of
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cancer, given the lower pH of the tumor microenvironment than general physiological
conditions. Cancer can reoccur at a range of times after resection, from the first week to the
second year 44-46. The DOX release profiles are thus very promising to prevent recurrence in
the early weeks after surgery.
The drug release rates are governed by the degradation and porosity of the fibers. After
the scaffolds are immersed in a buffer solution, their void volume is reduced due to the
swelling of the cross-linked gelatin (which can absorb water to form a hydrogel) 47, which
contributes to sustained release profiles for drug loaded fiber scaffolds. Over longer periods of
time, the fibers will begin to degrade through hydrolysis, losing their mechanical and
structural integrity and further promoting drug release. Clearly, the total amount of drug
released is higher from the SB-containing fibers, as is the rate of release (Table 4). As
discussed above, the SB can react in acidic media to form channels through which the drug
can diffuse into the release medium. The greater the content of SB, the more channels which
can form, and thus the faster the drugs are freed from the fibers and the greater the eventual
cumulative percentage release obtained. SB on the scaffold surface can also enhance
wettability 48, which further promotes DOX and ciprofloxacin release. It is important to note
that the results in Table 4 are fully consistent with clinical needs: the scaffolds given a rapid
initial, pH-sensitive, release of ciprofloxacin to inhibit inflammation and infection, and
long-term DOX release for the treatment of cancer.
In previous work 12 we have explored ciprofloxacin release from monolithic
PLCL/SB/drug and gelatin/SB/drug fibers. We found that the former had no pH-sensitivity,
regardless of the SB loading, while the latter show pH-responsive release over around 24 h.
By combining both PLCL and SB we are able to obtain systems that are both pH sensitive
and able to provide long-term sustained release.
Antibacterial activity
Figure 8 illustrates the antibacterial effects of the fiber scaffolds in terms of their
inhibition zones. All the fibers have similar behavior, as can be seen from the full data set in
Table 5. The samples loaded with ciprofloxacin kill all the bacteria around them, resulting in
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a clear inhibition zone of 30-40 mm. Generally speaking, the inhibition zones against S.
aureus are slightly greater than in the case of E. coli. This is consistent with the literature 49.
The addition of SB is found to have a small influence on the antibacterial properties of the
fibers: the higher the SB content, the greater the inhibitory zone. This is consistent with the
more rapid and greater extents of ciprofloxacin release observed with elevated SB
concentrations.
Biocompatibility
To evaluate the fibers’ biocompatibility, cells were seeded onto the different scaffolds
and their growth monitored over 5 days. The results of MTT cell viability measurements
obtained with non-cancerous L929 cells are given for the drug-loaded fibers in Figure 9(a)
and for the drug free analogues in Figure S4(a). As expected, the number of cells present
increases from day 1 to day 5 in all cases. Compared with the negative control (blank
coverslips), there is a noticeable increase in the number of cells on all the fiber scaffolds,
regardless of if they were drug-loaded or drug-free. Furthermore, an increase in the SB
content (for instance from G+ / P+ to GS3+ / P+) led to an increase in cell growth due to the
increase in surface wettability of the scaffolds 50. Overall, the data demonstrate that the fibers
are not toxic to non-cancerous cells, regardless of whether they have a drug loading or not.
The analogous data obtained with SMMC-7721 cells are presented in Figure 9(b) and
Figure S4(b). A rapid increase in the number of SMMC-7721 cells on the drug-free scaffolds
G- / P-, GS1- / P-, GS2- / P- and GS3- / P- is seen in Figure S4(b), analogous to the findings with
the non-cancerous L929 cells. In the case of the drug-loaded scaffolds, at all time points
studied there are fewer cells present than with the negative control. The drug-loaded scaffolds
thus have the ability to inhibit the growth of cancer cells over the 5-day time period. These
data are promising for the intended application of the fibers, although it is not possible to
draw any conclusions from them regarding the longer-term performance of the fibers.
However, given that DOX release continues over 26 – 30 days, it is thought that the fibers
would continue to have efficacy over this period.
Scaffold degradation
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SEM images of the fiber scaffolds after immersion in PBS or AA are presented in Figure
10. The fibers have merged after immersion, and their diameters become thicker compared
with the initial fibers. An increase in the amount of SB in the materials leads to the
generation of solid particles on the surface of the fibers (see Figure 10(d), 10(h)). This is
thought to be because CO2 generated from the SB created channels in the fibers, permitting
the migration of drug and SB to the fiber surface. These trends are apparent to a certain
extent after three days, but are much clearer after two months’ immersion. The reduction in
void volume in the fibers is likely to explain the fact that drug release does not reach 100%:
some of the drug is trapped deep inside the fibers, and as they swell and merge it becomes
increasingly difficult for these molecules to escape into the release milieu.
The pH values of the immersion buffers were also explored at the end of the
experiment (Figure 11). In both buffers, there is a small (< 0.5 pH units) decline in pH after
two months. This is likely to be in part a result of HCl in the DOX salt being freed from the
fibers 51. The degradation products of gelatin and PLCL are also acidic materials, and these
too will contribute to the lowering of the pH.
Overall, it is clear that partial degradation occurs over the two month timescale. This
compares favorably with the literature and clinical requirements. In a study by Cao et al. 52,
porous scaffolds of polyglycolic acid and beta-tricalcium phosphate showed partial
degradation 90 days after surgery. Wiltfang and co-worders 53 explored tricalcium
phosphate implants into minipig tibial bone defects, and found 60% degradation after 16
weeks and 80% at 28 weeks. Hence, the fibers have suitable biodegradability to act as
scaffolds after the resection of tumors.
Conclusions
Novel pH-sensitive coaxial fibers carrying ciprofloxacin and DOX were prepared in this
work, with the aim of making scaffolds which could be implanted following tumor resection
surgery. These were designed to provide an initial short-term release of ciprofloxacin, to
inhibit any infection and post-operative inflammation, followed by long-term DOX release to
destroy any residual cancerous tissue and avoid recurrence. The fibers comprised a
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biocompatible gelatin shell loaded with ciprofloxacin, and a poly(lactide-co-ε-caprolactone) 
core containing doxorubicin (DOX). SB was included in the shell to provide pH-sensitivity.
The fibers were generally smooth and cylindrical in shape, with clear core/shell compartments.
They have hydrophilic surfaces, as shown by contact angle measurements. In drug release
experiments, the shell rapidly released ciprofloxacin over a few days to quickly eliminate any
post-surgery infection or inflammation, while the core gave long-term release of DOX to kill
any residual cancer cells and prevent recurrence. The results of cytotoxicity tests
demonstrated that the drug-loaded fiber scaffolds stimulated the growth of non-cancerous
cells owing to their hydrophilic surfaces, but were able to inhibit the proliferation of
cancerous cells. The electrospun materials display appropriate mechanical properties for
scaffold materials, and suitable biodegradability to act as bioresorbable systems. Overall, the
materials prepared in this work have great potential to be used as implantable scaffolds in
order to prevent the recurrence of tumor after resection surgery.
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Figures
Figure 1. A schematic illustration of the experimental strategy used in this work.
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Figure 2. SEM images of the fibers generated: (a) G+ / P+; (b) GS1+ / P+; (c) GS2+ / P+; (d) GS3+ / P+; and (e-h)
the same fibers after cross-linking. The diameter distributions are shown below the images (AD: mean diameter;
SD: standard deviation). G+ / P+, GS1+ / P+, S2+ / P+, S3+ / P+ are drug-loaded coaxial fiber scaffolds with 0 %,
1 %, 3 %, and 5 % w/v SB in the shell solution respectively. Scale bar: 5 μm. 
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Figure 3. TEM images of the coaxial fibers: (a) G+ / P+; (b) GS1+ / P+; (c) GS2+ / P+; and (d) GS3+ / P+.
Figure 4. FTIR spectra of ciprofloxacin, DOX, monolithic gelatin and PLCL fibers, and the different coaxial
fibers.
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Figure 5. Stress/strain curves of monolithic gelatin and PLCL fibers, and the coaxial GS3+ / P+ material.
Figure 6. Ciprofloxacin release from the coaxial fibers in PBS (pH=7.4) or AA (pH=5.0).
26
Figure 7. DOX release from (a) monolithic PLCL fibers in PBS (pH=7.4) and (b) the coaxial fibers in PBS
(pH=7.4) or AA (pH=5.0).
Figure 8. Antibacterial activities of selected fiber samples: (a) GS3- / P- against E.coli; (b) GS3+ / P+ against
E.coli; (c) GS3- / P- against S. aureus; and, (d) GS3+ / P+ against S. aureus solid medium. Scale bar: 2 cm.
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Figure 9. (a) L929 and (b) SMMC-7721 cell proliferation on the drug-loaded fibers. * denotes p < 0.05 and ** p <
0.01 when compared with the blank coverslips.
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Figure 10. SEM images of fiber scaffolds after degradation studies. Images and fiber diameter distributions (AD:
mean diameter; SD standard deviation) are shown for (a) G+ / P+; (b) GS1+ / P+; (c) GS2+ / P+; and (d) GS3+ / P+
after 3 days immersion in PBS, and (e-h) for the same fibers after 3 days in AA. Results obtained after two
months’ immersion are given in (i-l) for PBS and (m-p) for AA (pH 5.0). Scale bar: 5 μm. 
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Figure 11. The pH values of buffer solutions after two months in contact with the fiber scaffolds.
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Tables
Table 1. Details of the electrospinning solutions used in this study. “G” denotes gelatin, “P” PLCL, and
“S” sodium bicarbonate; “+” indicates systems with a drug loading, and “-” those without drug.
Sample














Gelatin+ 15% 5% 10% - -
PLCL+ - - - 5% 1%
G+ / P+ 15% - 10% 5% 1%
GS1+ / P+ 15% 1% 10% 5% 1%
GS2+ / P+ 15% 3% 10% 5% 1%
GS3+ / P+ 15% 5% 10% 5% 1%
GS4+ / P+ 15% 7% 10% 5% 1%
Gelatin- 15% 5% - - -
PLCL- - - - 5% -
GS1- / P- 15% 1% - 5% -
GS2- / P- 15% 3% - 5% -
GS3- / P- 15% 5% - 5% -
Table 2. The contact-angles of the cross-linked fiber scaffolds.
Sample Contact-angle Sample Contact-angle
Gelatin+ 28±4.3° Gelatin- 32±3.6°
PLCL+ 121±3.5° PLCL- 124±2.7°
G+ / P+ 33±4.1°* G- / P- 35±2.8°*
GS1+ / P+ 21±2.7°* GS1- / P- 23±4.2°*
GS2+ / P+ 11±2.3°* GS2- / P- 12±0.2°*
GS3+ / P+ 10±1.2°* GS3- / P- 12±1.1°*
* denotes p < 0.05 when compared with the monolithic PLCL fibers.















Gelatin+ 1.48±0.2 22.5±1.1 Gelatin- 1.49±0.1 21.5±1.2
PLCL+ 3.13±0.3 5.09±1.1 PLCL- 3.03±0.3 6.09±1.3
G+ / P+ 2.00±0.3 25.8±1.7* G- / P- 2.30±0.7 27.1±1.9*
GS1+ / P+ 2.09±0.4 24.7±0.6 GS1- / P- 2.20±0.5 25.8±0.9
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GS2+ / P+ 2.21±0.7 22.2±1.1 GS2- / P- 2.03±0.4 25.3±1.3
GS3+ / P+ 2.57±0.2# 24.3±0.8 GS3- / P- 2.10±0.3 25.9±1.4
* denotes p < 0.05 when compared with the monolithic PLCL fibers, # denotes p < 0.05 when compared
with the monolithic gelatin fibers.







G+ / P+ GS1+ / P+ GS2+ / P+ GS3+ / P+
Ciprofloxacin
PBS 32 h 41±1 43±1 50±0.5 52±0.8
AA 31 h 41±1 71±2 75±1 80±0.4
DOX
PBS 26 days 30±2 38±2 41±0.8 45±0.7
AA 32 days 30±1 52±0.9 61±1 67±1
Table 5. Inhibition zone diameters for the coaxial fiber scaffolds.






GS1+ / P+ 33±3.8 34±3.0
GS2+ / P+ 35±3.9 36±2.4#
GS3+ / P+ 37±2.2* 38±4.1
Gelatin- - -
PLCL- - -
GS1- / P- - -
GS2- / P- - -
GS3- / P- - -
* denotes p < 0.05 when compared with the monolithic PLCL fibers, # denotes p < 0.05 when compared
with the monolithic gelatin fibers.
